Topical timolol 0.5% gel-forming solution for erythema in rosacea: A quantitative, split-face, randomized, and rater-masked pilot clinical trial

Tsai, Jerry; Chien, Anna L.; Kim, Noori; Rachidi, Saleh; Connolly, B.; Lim, Hester Gail; César, Sabrina Sisto Alessi; Kang, Sewon; Garza, Luis A.

doi:10.1016/j.jaad.2021.01.098

Cited by 7 publications

(6 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After switching to application of topical timolol on both sides of the face, there was a significant improvement in the longer‐treated side at week 12. Rebound erythema was observed four weeks after discontinuation of treatment 17 . The efficacy in our study was quite different to that reported by Tsai.…”

Section: Discussioncontrasting

confidence: 99%

See 1 more Smart Citation

A randomized, controlled, split‐face study of topical timolol maleate 0.5% eye drops for the treatment of erythematotelangiectatic rosacea

Wei

Hamblin

Wen

2021

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Rosacea is a chronic inflammatory cutaneous disease with varying prevalence. The pathophysiologic mechanisms include an interaction between genetic and environmental factors, neurovascular dysregulation, and increased immune response. These mechanisms lead to the main symptoms of inflammation, vasodilation, and angiogenesis. The classification of rosacea involves four subtypes designated as follows: subtype 1, erythematotelangiectatic; subtype 2, papulopustular; subtype 3, phymatous; subtype 4, ocular. Rosacea usually commences with a flush-like temporary dilation of capillaries and transient erythema. Once the facial vasculature becomes chronically dilated, persistent erythema can become established, known as erythematotelangiectatic rosacea (ETR) or subtype 1. [1][2][3] However, the current recommendations now suggest that patients with rosacea should be characterized by individual clinical signs and symptoms, because the focus on subtypes tended to ignore the progression from one type to another. New scientific evidence has

show abstract

Section: Discussioncontrasting

confidence: 99%

“…Rebound erythema was observed four weeks after discontinuation of treatment. 17 The efficacy in our study was quite different to that reported by Tsai. There may be two reasons for this.…”

Section: Ta B L Econtrasting

confidence: 99%

A randomized, controlled, split‐face study of topical timolol maleate 0.5% eye drops for the treatment of erythematotelangiectatic rosacea

Wei

Hamblin

Wen

2021

J of Cosmetic Dermatology

View full text Add to dashboard Cite

show abstract

“…19 Reduction in erythematotelangectatic rosacea was seen in an eight-patient trial reported by Al Mokadem et al 19 ; however, at 16 weeks, the erythema recurred. 20 In a case study looking at post-acne erythema and hyperpigmentation, both showed improvement with topical timolol on subjective dermoscopic evaluation following 3 months of timolol therapy. 21…”

Section: Postsurgical Woundsmentioning

confidence: 99%

Topical timolol in dermatology: infantile haemangiomas and beyond

Alzaid

Al-Naseem

Al‐Niaimi

et al. 2022

Clin Experimental Derm

View full text Add to dashboard Cite

Timolol, a nonselective b-adrenergic receptor blocker, is well-tolerated and is becoming increasingly popular in dermatology, especially in the management of infantile haemangioma (IH). Its effects are mainly due to vasoconstriction, inhibition of angiogenesis and keratinocyte migration promotion for re-epithelialization and wound healing. We review the evidence behind the use of timolol in several dermatological conditions including IH, pyogenic granulomas, Kaposi sarcoma, chronic wound healing, postsurgical wounds, acne vulgaris, rosacea, eczema and red scrotum syndrome.

show abstract

“…85 In a phase I trial, patients who applied timolol 0.5% gel twice-daily observed significant reduction in erythema (P < .001) by week 12, but with recovery of erythema at week 16. 86,87 Lotilaner (TP-04). Lotilaner is an antiparasitic that has been used in treated Demodex blepharitis and is being evaluated in rosacea due to its efficacy in eradicating Demodex mites.…”

Section: Proteasome Inhibitor (Acu-d1mentioning

confidence: 99%

Section: Targets Of Rosacea Treatmentsmentioning

confidence: 99%

Rosacea: Pathogenesis and Therapeutic Correlates

Geng,

Bourkas,

Mufti

et al. 2024

J Cutan Med Surg

View full text Add to dashboard Cite

Rosacea is a chronic inflammatory condition of which there is no cure. The pathogenesis of rosacea is likely multifactorial, involving genetic and environmental contributions. Current understanding suggests that pro-inflammatory pathways involving cathelicidins and inflammasome complexes are central to rosacea pathogenesis. Common rosacea triggers modulate these pathways in a complex manner, which may contribute to the varying severity and clinical presentations of rosacea. Established and emerging rosacea treatments may owe their efficacy to their ability to target different players in these pro-inflammatory pathways. Improving our molecular understanding of rosacea will guide the development of new therapies and the use of combination therapies.

show abstract

Topical timolol 0.5% gel-forming solution for erythema in rosacea: A quantitative, split-face, randomized, and rater-masked pilot clinical trial

Cited by 7 publications

References 4 publications

A randomized, controlled, split‐face study of topical timolol maleate 0.5% eye drops for the treatment of erythematotelangiectatic rosacea

A randomized, controlled, split‐face study of topical timolol maleate 0.5% eye drops for the treatment of erythematotelangiectatic rosacea

Topical timolol in dermatology: infantile haemangiomas and beyond

Rosacea: Pathogenesis and Therapeutic Correlates

Contact Info

Product

Resources

About